CIPLA

Cipla Limited is an Indian multinational

pharmaceutical company, headquartered in Mumbai,
India. Cipla primarily develops medicines to treat
respiratory, cardiovascular disease, arthritis,
diabetes, weight control and depression; other
medical conditions.

As of 17 September 2014, its market capitalisation

was ₹49,611.58 crore (equivalent to ₹530 billion or
US$7.5 billion in 2019), making it India's 42nd largest
publicly traded company by market value.
 SALES DATA FOR CIPLA

YEARLY RESULTS OF CIPLA (IN RS. CR.) MAR '21 MAR '20 MAR '19 MAR '18 MAR '17  

Net Sales/Income from operations 13,610.02 12,220.22 11,968.44 11,004.44 10,637.08  

Other Operating Income 290.56 438.93 405.57 440.37 337.50  

Total Income From Operations 13,900.58 12,659.15 12,374.01 11,444.81 10,974.58  

EXPENDITURE  

Consumption of Raw Materials 3,262.29 2,999.17 3,112.25 3,303.31 2,956.04  

Purchase of Traded Goods 1,847.85 1,363.12 1,259.21 1,064.23 1,128.99  

Increase/Decrease in Stocks -9.93 -43.08 136.70 -212.05 56.27  

Power & Fuel -- -- -- -- --  

Employees Cost 2,038.88 1,911.08 1,839.84 1,785.94 1,728.97  

Depreciation 556.11 599.78 569.72 529.61 499.97

 Geographical Presence

INDIA
Cipla is the 3rd largest pharmaceutical company in India, with product portfolio spanning across
various therapeutic areas including Respiratory, Anti-infectives, Cardio-metabolic, Gastro and
Urology .
The company's strong brand equity, product range and unique dosage forms help it stand out
in the fiercely competitive Indian pharmaceutical industry environment.
Moreover, Cipla is the market leader in Respiratory and Urology and have 22 brands feature
among the top 300 brands of IPM. In FY 18-19, Cipla’s overall domestic business contributed
to 39% of the global revenues.
USA
Cipla USA Inc., the US subsidiary of Cipla Limited, is the first Indian company to be approved by US
FDA in 1985. Headquartered in Miami, FL, Cipla USA Inc.has supported the development of more than
170 ANDAs till date. Over last 5 years, Cipla has significantly expanded its portfolio and presence in
the world’s largest pharmaceutical market of US.
Building further on the commercial front end acquired through InvaGen Pharmaceuticals Inc. and
Exelan Pharmaceuticals Inc, Cipla has remained amongst the top 12 most dispensed companies in
the US during FY 18-19. The North America business today represents 21% of its overall revenues.

EUROPE
Cipla is present in almost all countries in the European region with 4 DTMs in Germany, Norway, Spain
and the UK. The change in the business model for the European countries, moving from DTM model
to a partnership- led B2B model, has improved profitability significantly. From a Therapy standpoint,
while respiratory continues to remain a focus area, Oncology and complex injectable will be a part of
the differentiated product portfolio strategy in the region
South Africa, Sub-Saharan Africa and Cipla Global Access (SAGA)

Cipla Med pro, a 100% subsidiary of Cipla Limited, has a strong presence across various therapeutic
categories in South Africa. Cipla is one of the largest pharmaceutical companies in South Africa by
volume and third largest by value. Cipla is recognized widely in Africa for the pioneering role it played in
ensuring access to HIV/Aids medication with its innovative tripe-combination anti-retroviral (ARV) in 2001.
This was available to patients at less than $1 a day – a significant cost saving – thereby allowing access
to millions of people living with HIV/Aids and saving millions of lives in Africa alone.
The company's manufacturing facility at Durban provides a competitive edge and is the first
Pharmaceutical Inspection Convention (PIC) compliant facility in the South Africa. The company also
have a world-class distribution Centre in Cape Town and satellite offices situated throughout the country
to house commercial and regulatory functions
AUSTRALIA
Based in Melbourne, Cipla Australia has a vast pipeline of
products that are supplied in Australia as well as US & EU.
Millions of Australians have access to a Cipla
manufactured product through its community pharmacy
partners around Australia. The company's state-of-the-art
manufacturing facilities are TGA approved as well as
being USFDA (USA) and MHRA (UK) approved. Cipla
Australia has over 200 registered; formulations; with TGA
through partnerships with market leaders and on its own. 3
THANK YOU